Randomised trial of octreotide for long term management of cirrhosis after variceal haemorrhage

British Medical Journal

Volumn 315, Issue 7119, 1997, Pages 1338-1341

  Jenkins, Spencer A ^a   Baxter, John N ^a   Critchley, Mair ^a   Kingsnorth, Andrew N ^a   Makin, Carol A ^a   Ellenbogen, Simon ^a   Steven Grime, J ^a   Love, Janet G ^b   Sutton, Robert ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; AMINOPHENAZONE; BILIRUBIN; OCTREOTIDE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIARY COLIC; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; ENDOSCOPIC SCLEROTHERAPY; HUMAN; INJECTION PAIN; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER METABOLISM; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL; TREATMENT OUTCOME; VARICOSIS;

EID: 0030716412     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.315.7119.1338     Document Type: Article

References (24)

1. Terblanche J, Bornman PC, Kahn D, Jonker MAT, Campbell JAH, Wright J, et al. Failure of repeated injection sclerotherapy to improve long-term survival after oesophageal variceal bleeding: a five-year prospective controlled clinical trial. Lancet 1983;ii:1328-32.
2. Copenhagen Esophageal Varices Sclerotherapy Project Sclerotherapy after first variceal hemorrhage in cirrhosis: a randomised multicentre trial. N Engl J Med 1984;311:594-600.
3. Westaby D, MacDougall BR, Williams R. Improved survival following injection sclerotherapy for esophageal varices. Final analysis of a controlled trial. Hepatology 1985;5:827-30.
4. Stiegmann GV, Goff JS, Michaletz-Onody PA, Korolv J, Liebermann D, Saeed ZA, et al. Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding oesophageal varices. N Engl J Med 1992;326:1527-32.
5. Gimson AES, Ramage JK, Panoz MZ, Hayllar K, Harrison PM, Williams R, et al. Randomised trial of variceal bleeding ligation versus injection sclerotherapy for bleeding oesophageal varices. Lancet 1993;342:391-4.
6. Besson I, Ingrand P, Person B, Bouthroux D, Heresbach D, Bernard P, et al. Sclerotherapy with or without octreotide for acute variceal bleeding. N Engl J Med 1995;333:555-60.
7. Merkel C, Morabito A. Adding beta-blockers to sclerotherapy in the prevention of variceal rebleeding - a meta-analysis assessment. J Hepatol 1994;21:918-9.
8. Feu F, Garciapagan JC, Bosch J, Luca A, Teres J, Escorsell A, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995;346:1056-9.
9. Hanisch F, Dortenbach J, Usadel KH. Somatostatin in acute bleeding oesophageal varices. Pharmacology and rationale for use. Drugs 1992;44:24-35.
10. Battershill PE, Clissold SP. Octreotide: a review of its pharmacodynamic and phannacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs 1989;38:658-702.
11. Kuhn JM, Legrand A, Ruiz JM, Obach R, Deronzan J, Thomas F. Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers. Br J Pharmacol 1994;38:213-9.
12. Sieber CC, Mosca PG, Groszmann RJ. Effect of somatostatin on mesenteric vascular resistance in normal and portal hypertensive rats. Am J Physiol 1992;262:G274-7.
13. + retention in portal hypertensive rats. Gastroenterology 1993;104:575-9.
14. Navasa M, Bosch J, Chesta J, Rodes J. Hemodynamic effects of subcutaneous administration of SMS 201-995, a long-acting somatostatin analog in patients with cirrhosis and portal hypertension. J Hepatol 1988;123:S64.
15. Baxter JN, Jenkins SA, Day DW, Shields R. Effects of a somatostatin analogue (SMS 201-995) on hepatic and splenic reticuloendothelial system function in the rat. Br J Surg 1985;72:1005-8.
16. Child CG, Turcotte JG. Surgery and portal hypertension. in: Child CG, Dunphy JE, eds. Major problems in clinical surgery: the liver and portal hypertension. Vol 1. Philadelphia: Saunders, 1964:1-85.
17. 14C] aminoyprine. Ann intern Med 1975;83:632-9.
18. Grime JS, Critchley M, Roberts CM, Morris AI. Single photon emission tomography in the evaluation of chronic liver disease. Nucl Med Commun. 1983;3:282-9.
19. Gardner MJ, Altman DG. Statistics with confidence. London: British Medical Journal, 1989.
20. Jenkins SA, Baxter JN, Corbett WA, Shields R. The effects of a somatostatin analogue SMS 201-995 on hepatic haemodynamics in the pig and on intravariceal pressure in man. Br J Surg 1985;72:1009-12.
21. Yates J, Nott DM, Kynaston H, Davies N, Jin Lai L, Billington D, et al. Hypovolaemia and reperfusion in portal hypertension: effects of somatostatin, octreotide and vasopressin. Br J Surg 1994;81:750.
22. Landa I, Arias J, Gomez M, Quadros M, Moreno A, Balibrea JL. Cytoprotective effect of somatostatin in a rat model of hepatic ischemic reperfusion. Hepatology 1992;16:1474-6.
23. Rimola A, Soto R, Bory F, Arrowe V, Piera C, Rodes J. Reticuloendothelial system phagocytic activity in cirrhosis and its relationship to bacterial infections and prognosis. Hepatology 1984;4:53-8.
24. Lancranjan I, Bruns C, Grass P, Jaquet P, Jervell J, Kendall-Taylor P, et al. Sandostatin-LAR(R): pharmacokinetics, pharmacodynamics, efficacy and tolerability in acromegalic patients. Metabolism 1995;44:18-26.